Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

A person is microdosing estrogen for hair loss after finasteride and dutasteride failed, risking feminizing effects. Alternatives like minoxidil, RU58841, or hair transplants are suggested.

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

A user's 11-month progress using 5mg oral minoxidil for hair loss. The user reported significant hair regrowth, including on the beard and eyebrows, and experienced minor side effects like headaches and increased body hair.

A 51-year-old woman switched from Minoxidil to Maneup, a copper peptide treatment, experiencing initial hair loss but later regrowth with different hair texture. Users debated Maneup's effectiveness, with some considering it alongside finasteride.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

A user applied minoxidil to their pubic hair for 3 months, resulting in hair growth over 4 inches, and is considering using it for a scalp hair transplant. They plan to continue the treatment despite their wife's disapproval.

Minoxidil is highly toxic to cats and can cause fatal heart issues. Users recommend switching to oral minoxidil to protect pets.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A user is using 2.5 mg minoxidil for beard growth and considering increasing the dose to 5 mg for more body hair gains, despite experiencing a bald spot on the scalp. Another user questions the desire for more body hair, suggesting it's not appealing.

The conversation discusses the use of TRT, dutasteride, minoxidil, and potentially RU58841 for hair loss. Concerns about the risk of developing Cutis verticis gyrata with minoxidil and TRT are raised.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

Minoxidil alone is not effective for significant hair regrowth; combining it with finasteride or dutasteride is necessary. Additional treatments like hair transplants, microneedling, or oral medications are recommended for better results.

The conversation humorously discusses exaggerated hair growth results using 500mg finasteride and 1000mg minoxidil daily, with side effects including a bloody nose and lowered libido. It also jokes about microneedling, hair transplants, and elephants, suggesting the post is satirical.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

A dermatologist prescribed methionine with vitamins for hair loss, but the user is doubtful and plans to seek finasteride in France. The user is unsure why finasteride or minoxidil wasn't prescribed, suspecting concerns about side effects or strength.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.

The user regained most of their hair using Minoxidil, Finasteride, and Dermarolling. They found Dermarolling particularly effective, as it promotes growth factors and improves hair thickness.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.